ML Bio Solutions Inc.
- Address
- 1800 Owens Street Suite C1200
Sponsor Overview
Specializations
Neuromuscular Disorders
ML Bio Solutions Inc. focuses on limb girdle muscular dystrophy 2I/R9, with clinical research centered on the treatment of progressive muscle weakness and related functional impairment in this rare inherited disorder.
- LGMD2I/R9
- Muscular dystrophy
- Inherited myopathy
The sponsor’s clinical interest is directed toward therapies intended to address the underlying disease burden in a rare neuromuscular disease population.
Muscle Function and Mobility
Research activity also extends to outcomes linked with skeletal muscle performance, including mobility, strength, and day-to-day physical function in patients affected by LGMD2I/R9.
- Muscle strength
- Physical function
- Mobility impairment
These areas reflect a therapeutic emphasis on preserving movement and functional capacity in a chronic progressive condition.
Rare Disease Therapeutics
The company’s clinical portfolio includes investigation of rare disease treatment options, with attention to targeted approaches for genetic muscle disorders that have limited established therapies.
- Rare genetic disease
- Targeted therapy
- Orphan disease
This therapeutic domain aligns with development efforts for conditions requiring specialized clinical evaluation and disease-specific intervention.
Clinical Safety and Efficacy
ML Bio Solutions Inc. is actively involved in assessing clinical efficacy and safety in patients with LGMD2I/R9, supporting medical research focused on tolerability and therapeutic impact in a small patient population.
- Therapeutic efficacy
- Safety evaluation
- Patient outcomes
The research landscape is centered on evidence generation for a candidate therapy intended for a specific neuromuscular indication.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ribitol (BBP-418) in Limb Girdle Muscular Dystrophy 2I/R9 |  Denmark Germany Italy Norway The Netherlands | Not Recruiting |
| Open-Label Extension Study Assessing Long-Term Safety and Efficacy of Oral Ribitol (BBP-418) in Adults with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9) | Denmark Germany Italy Norway The Netherlands | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 6 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
Partnered Research Centres
6 centres- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- Albinusdreef 2, 2333 ZA Leiden
- Address
- Blegdamsvej 9, 2100 Copenhagen
- Address
- Hufelandstrasse 55, Holsterhausen, 45147 Essen
- Address
- Sykehusvegen 38, 9019 Tromsø
Want to get in touch with this sponsor?
Send a question and we'll pass it on to ML Bio Solutions Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.